Ledyard National Bank Has $636,000 Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Ledyard National Bank trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,901 shares of the medical equipment provider’s stock after selling 340 shares during the period. Ledyard National Bank’s holdings in Hologic were worth $636,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Nordea Investment Management AB raised its stake in Hologic by 4.5% in the third quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock valued at $113,077,000 after buying an additional 69,494 shares during the period. Louisiana State Employees Retirement System bought a new position in Hologic in the 4th quarter valued at about $1,057,000. Pathstone Family Office LLC lifted its position in Hologic by 96.0% during the third quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock worth $643,000 after acquiring an additional 4,542 shares during the last quarter. Ontario Teachers Pension Plan Board boosted its holdings in shares of Hologic by 186.7% during the third quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider’s stock worth $2,665,000 after acquiring an additional 25,010 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its position in shares of Hologic by 145.3% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 468 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Down 0.9 %

HOLX traded down $0.67 during trading on Tuesday, reaching $75.96. 307,804 shares of the company’s stock were exchanged, compared to its average volume of 1,739,426. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. Hologic, Inc. has a one year low of $64.02 and a one year high of $87.88. The firm has a fifty day moving average price of $76.08 and a two-hundred day moving average price of $72.88. The stock has a market capitalization of $17.83 billion, a PE ratio of 36.32, a price-to-earnings-growth ratio of 2.57 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $989.32 million. During the same period last year, the company earned $1.07 EPS. Hologic’s revenue for the quarter was down 5.7% compared to the same quarter last year. As a group, equities research analysts forecast that Hologic, Inc. will post 4.01 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now owns 48,611 shares in the company, valued at $3,670,130.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares of the company’s stock, valued at $119,802.12. The disclosure for this sale can be found here. Insiders own 1.75% of the company’s stock.

Analyst Ratings Changes

HOLX has been the subject of several research reports. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. Raymond James boosted their price objective on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. StockNews.com cut Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Wednesday, April 10th. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $87.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.